secwatch.observer — SEC 8-K summary
======================================

Issuer:     Provention Bio, Inc. (—)
CIK:        0001695357
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001493152-23-013783
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi completes acquisition of Provention Bio for $25.00 per share
-------------------------------------------------------------------

- Tender offer expired with 74,490,556 shares tendered (~73% of outstanding); all accepted at $25.00 per share.
- Merger completed under DGCL Section 251(h); each share converted to cash $25.00, net of withholding.
- All outstanding Company Stock Options cancelled; holders receive cash for excess of $25.00 over exercise price.
- Board replaced; Michael Tolpa, Olivier Bogillot, Debora Pellicano appointed directors; new officers named.
- Company requested Nasdaq halt and delist; intends to deregister shares under Exchange Act.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/0001493152-23-013783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1695357/000149315223013783/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-013783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer